Cargando…

HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery

Recently, numerous polymer materials have been employed as drug carrier systems in medicinal research, and their detailed properties have been thoroughly evaluated. Water-soluble polymer carriers play a significant role between these studied polymer systems as they are advantageously applied as carr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chytil, Petr, Kostka, Libor, Etrych, Tomáš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916469/
https://www.ncbi.nlm.nih.gov/pubmed/33578756
http://dx.doi.org/10.3390/jpm11020115
_version_ 1783657484021399552
author Chytil, Petr
Kostka, Libor
Etrych, Tomáš
author_facet Chytil, Petr
Kostka, Libor
Etrych, Tomáš
author_sort Chytil, Petr
collection PubMed
description Recently, numerous polymer materials have been employed as drug carrier systems in medicinal research, and their detailed properties have been thoroughly evaluated. Water-soluble polymer carriers play a significant role between these studied polymer systems as they are advantageously applied as carriers of low-molecular-weight drugs and compounds, e.g., cytostatic agents, anti-inflammatory drugs, antimicrobial molecules, or multidrug resistance inhibitors. Covalent attachment of carried molecules using a biodegradable spacer is strongly preferred, as such design ensures the controlled release of the drug in the place of a desired pharmacological effect in a reasonable time-dependent manner. Importantly, the synthetic polymer biomaterials based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers are recognized drug carriers with unique properties that nominate them among the most serious nanomedicines candidates for human clinical trials. This review focuses on advances in the development of HPMA copolymer-based nanomedicines within the passive and active targeting into the place of desired pharmacological effect, tumors, inflammation or bacterial infection sites. Specifically, this review highlights the safety issues of HPMA polymer-based drug carriers concerning the structure of nanomedicines. The main impact consists of the improvement of targeting ability, especially concerning the enhanced and permeability retention (EPR) effect.
format Online
Article
Text
id pubmed-7916469
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79164692021-03-01 HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery Chytil, Petr Kostka, Libor Etrych, Tomáš J Pers Med Review Recently, numerous polymer materials have been employed as drug carrier systems in medicinal research, and their detailed properties have been thoroughly evaluated. Water-soluble polymer carriers play a significant role between these studied polymer systems as they are advantageously applied as carriers of low-molecular-weight drugs and compounds, e.g., cytostatic agents, anti-inflammatory drugs, antimicrobial molecules, or multidrug resistance inhibitors. Covalent attachment of carried molecules using a biodegradable spacer is strongly preferred, as such design ensures the controlled release of the drug in the place of a desired pharmacological effect in a reasonable time-dependent manner. Importantly, the synthetic polymer biomaterials based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers are recognized drug carriers with unique properties that nominate them among the most serious nanomedicines candidates for human clinical trials. This review focuses on advances in the development of HPMA copolymer-based nanomedicines within the passive and active targeting into the place of desired pharmacological effect, tumors, inflammation or bacterial infection sites. Specifically, this review highlights the safety issues of HPMA polymer-based drug carriers concerning the structure of nanomedicines. The main impact consists of the improvement of targeting ability, especially concerning the enhanced and permeability retention (EPR) effect. MDPI 2021-02-10 /pmc/articles/PMC7916469/ /pubmed/33578756 http://dx.doi.org/10.3390/jpm11020115 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chytil, Petr
Kostka, Libor
Etrych, Tomáš
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title_full HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title_fullStr HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title_full_unstemmed HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title_short HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
title_sort hpma copolymer-based nanomedicines in controlled drug delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916469/
https://www.ncbi.nlm.nih.gov/pubmed/33578756
http://dx.doi.org/10.3390/jpm11020115
work_keys_str_mv AT chytilpetr hpmacopolymerbasednanomedicinesincontrolleddrugdelivery
AT kostkalibor hpmacopolymerbasednanomedicinesincontrolleddrugdelivery
AT etrychtomas hpmacopolymerbasednanomedicinesincontrolleddrugdelivery